We are Sorry, This Page doesn't Exist

Sometimes it's just the relative performance that really matters to investors. Imagine saying, "Gee, that's great because it's only down 10% in this awful stock market.".....»»

Source: JPM Chase   My favorite market chart book is out, and as always, its filled with 86 pages of great charts and insightful ideas. There are a few new(ish) sides in the deck and a couple of unusual charts worth highlighting. My sugg.....»»

The great rotation in equity markets into value stocks continues apace and if investors on Wall Street have been uncertain about its durability, the performance of at least one popular ETF over the past three months may deliver a lasting impression......»»

The great rotation in equity markets into value stocks continues apace and if investors on Wall Street have been uncertain about its durability, the performance of at least one popular ETF over the past three months may deliver a lasting impression......»»

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter results. Want the .....»»

Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) repo.....»»

Alphabet Inc.’s new financial disclosures made it possible for investors to actually figure out the financial performance of one of its individual businesses, a rarity for Google’s parent company......»»

We expect investors to focus on the performance of newly launched drugs when Novartis (NVS) reports its fi.....»»

Investors are expected to focus on Eylea's performance and Dupixent's uptake when Regeneron Pharmaceuticals, Inc. (REGN) reports first-quarter 2018 results on May 3. .....»»

On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products. Horizon Ph.....»»

Investors are exepcted to focus on the performance of EpiPen, newly launched drugs and the progress of the company's biosimilars pipeline when Mylan (MYL) reports results for the Q1. Mylan .....»»

With a strong Q1 performance will investors' focus shift to.....»»

These sectors have seen double-digit revenue growth in Q1. This puts these ETFs in focus. As the Q1 reporting cycle is drawing to a close, investors must be interested in finding out the performance of the Zacks classified 16 sectors of the S&P.....»»

BlueMountain Hires Four Portfolio Managers to Build Out Relative-Value Focus (Reuters) NEW YORK (Reuters) – BlueMountain Capital Manag.....»»

Seth Klarman is widely considered to be one of the best value investors of all-time. He has been able to achieve such outstanding Returns for his investors because of his focus.....»»

Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results. Mylan N.V. MYL is scheduled to report third-qu.....»»

Momentum stock investors will love VMware (VMW) seeing its favorable price performance.....»»

The firearms industry is improving, while outdoor gear is becoming a more important part of the gunmaker's performance......»»

In every period of rising interest rates since 1990, the S&P 500 delivered positive performance, according to BMO's Brian Belski. Federal Reserve.....»»

The St. Augustine-based company enjoyed its best first quarter in company history and expects to improve upon that performance this quarter......»»